REFRACTORY EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Clinical trials for REFRACTORY EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR trials appear
Sign up with your email to follow new studies for REFRACTORY EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug shows promise for kids with rare, Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called larotrectinib in children and young adults (ages 1 to 21) whose advanced or recurrent solid tumors, lymphoma, or histiocytic disorders have a specific genetic change called an NTRK fusion. The drug works by blocking enzymes that help cancer cells gr…
Matched conditions: REFRACTORY EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:05 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers had come back or stopped responding to treatment and had specific gene changes (ALK or ROS1). The goal was to see if the drug could shrink o…
Matched conditions: REFRACTORY EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for kids with resistant cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had spread, returned, or stopped responding to treatment. The drug targets tumors with specific changes in FGFR genes. The main goal was to see if the drug could shrink or stop t…
Matched conditions: REFRACTORY EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC